Annora Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Annora Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $56.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Annora Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $56.8M Trade | TransData Nexus

Annora Pharma Private Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $56.8M Total Trade · DGFT Verified

Annora Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $56.8M across 13 products in 9 therapeutic categories. Based on 2,057 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Calcium ($10.0M), Magnesium ($8.6M), Atorvastatin ($8.4M).

Annora Pharma Private Limited — Export Portfolio & Destination Treemap

Annora Pharma Private Limited pharmaceutical export portfolio — 13 products across 9 therapeutic categories. Source: Indian Customs (DGFT).

Who is Annora Pharma Private Limited? — Company Overview & Market Position

Annora Pharma Private Limited, incorporated on November 26, 2015, is a privately held pharmaceutical company based in Annaram, Telangana, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24100TG2015PTC101939, and it is registered under the Registrar of Companies, Hyderabad.

The authorized share capital of Annora Pharma is ₹316 crore, with a paid-up capital of ₹271 crore. As of March 2026, the company employs between 1,001 and 5,000 individuals, reflecting its significant presence in the pharmaceutical manufacturing sector. The registered office is located at Sy.No.261, Plot No.5,7,8,9,13 and 14, Annaram Village, Gummadidala Mandal, Telangana 502313, India.

What Does Annora Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Calcium$10.0M 2Magnesium

Product Portfolio — Top 13 by Export Value

Annora Pharma Private Limited exports 13 pharmaceutical products across 9 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Calcium	Vitamins & Supplements	$10.0M	475	1.1%	10
2	Magnesium	Vitamins & Supplements	$8.6M	197	2.4%	5
3	Atorvastatin	Cardiovascular	$8.4M	426	0.8%	15
4	Famotidine	Gastrointestinal	$8.1M	435	14.5%	2
5	Mesalamine	Gastrointestinal	$7.8M	157	0.6%	4
6	Esomeprazole	Gastrointestinal	$5.7M	155	1.2%	9
7	Darunavir	Antiviral & HIV Medications	$2.8M	55	4.5%	4
8	Colchicine	Lipid & Metabolism	$2.1M	78	10.2%	2
9	Itraconazole	Antifungals	$1.4M	27	4.9%	2
10	Linezolid	Advanced Antibiotics	$1.1M	21	2.8%	5
11	Enalapril	Cardiovascular	$450.0K	9	0.2%	15
12	Theophylline	Respiratory	$290.4K	10	1.8%	10
13	Efavirenz	Antivirals	$208.6K	12	0.3%	15

Annora Pharma Private Limited exports 13 pharmaceutical products across 9 therapeutic categories with a total export value of $56.8M. The top category is Gastrointestinal (38.0% of portfolio), followed by Vitamins & Supplements (32.6%), indicating a concentrated portfolio with the top 5 products accounting for 75.5% of total export value.

Annora Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Annora Pharma operates a state-of-the-art manufacturing facility situated in Annaram, Telangana. This plant is equipped to produce a diverse range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, adhering to global quality standards. The facility's strategic location in Telangana provides logistical advantages for both domestic and international distribution.

3Key Leadership

The leadership team at Annora Pharma comprises experienced professionals committed to steering the company towards growth and innovation. Key executives include:

Palleswara Rao Palapatla Govada: Director since November 26, 2015.

Mahesh Ramappa Kamalamma Hassan: Director since March 30, 2018.

Govindaraju Bhavani: Director since June 30, 2022.

Kiran Kumar Manikwar: Company Secretary since February 24, 2025.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Annora Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Annora Pharma has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has submitted Abbreviated New Drug Applications (ANDAs) to the U.S. Food and Drug Administration (FDA), seeking approval for generic versions of various pharmaceutical products. For instance, in January 2025, Annora Pharma received a Paragraph IV notice of certification from BioCryst Pharmaceuticals, indicating its intent to market a generic version of ORLADEYO in the U.S. prior to the expiration of certain patents.

In the European Union, Annora Pharma has pursued marketing authorizations for its products, aligning with the European Medicines Agency's (EMA) stringent regulatory requirements. The company has also engaged with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the Therapeutic Goods Administration (TGA) in Australia, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to ensure compliance with each region's regulatory standards. These efforts underscore Annora Pharma's commitment to providing high-quality pharmaceutical products in key international markets.

2Emerging Markets

Annora Pharma has strategically targeted emerging markets in Africa, Latin America, and Southeast Asia to diversify its global footprint. The company's adherence to World Health Organization (WHO) prequalification standards has facilitated access to these regions, enabling the supply of essential medicines to underserved populations. By obtaining WHO prequalification, Annora Pharma demonstrates its commitment to maintaining high-quality manufacturing practices, thereby enhancing its reputation and marketability in these emerging markets.

Annora Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Annora Pharma has actively engaged with the U.S. Food and Drug Administration (FDA) to expand its product offerings in the U.S. market. The company has submitted multiple Abbreviated New Drug Applications (ANDAs) for generic versions of various pharmaceutical products. In January 2025, Annora Pharma received a Paragraph IV notice of certification from BioCryst Pharmaceuticals, indicating its intent to market a generic version of ORLADEYO in the U.S. prior to the expiration of certain patents.

The company's FDA facility registrations and approved ANDAs reflect its commitment to meeting the agency's rigorous standards for safety, efficacy, and quality. Annora Pharma's proactive approach in seeking FDA approvals underscores its dedication to providing high-quality generic pharmaceutical products to the U.S. market.

2WHO & EU GMP

Annora Pharma's adherence to World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards underscores its commitment to producing high-quality pharmaceutical products. The company's manufacturing facilities are designed to meet these stringent requirements, ensuring that its products are safe, effective, and of consistent quality. By aligning with WHO and EU GMP standards, Annora Pharma enhances its credibility and competitiveness in both regulated and emerging markets.

Annora Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Annora Pharma operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. Top competitors include Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Ltd., and Lupin Ltd. These companies have established a strong presence in both domestic and international markets, offering a wide range of pharmaceutical products.

In terms of market share, Annora Pharma's top five exported products—Calcium, Magnesium, Atorvastatin, Famotidine, and Mesalamine—collectively account for 75.5% of its total export value. This concentration indicates a focused product portfolio, which can be advantageous in terms of operational efficiency but may also expose the company to risks associated with market fluctuations in these specific therapeutic categories.

2Key Differentiators

Annora Pharma's key differentiators include its commitment to adhering to international regulatory standards, such as WHO and EU GMP, ensuring the production of high-quality pharmaceutical products. The company's strategic focus on both regulated and emerging markets allows it to leverage growth opportunities across diverse regions. Additionally, Annora Pharma's proactive engagement with regulatory bodies, including the FDA, demonstrates its dedication to compliance and market expansion.

Strategic Position

Buyer Due Diligence Brief — Evaluating Annora Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Annora Pharma has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $56.8 million USD across 2,057 shipments. The company's portfolio includes 13 products across nine therapeutic categories, indicating a diversified product range. The top five products—Calcium, Magnesium, Atorvastatin, Famotidine, and Mesalamine—collectively account for 75.5% of the total export value, highlighting a focused yet substantial presence in key therapeutic areas.

The company's consistent export volume and adherence to international quality standards suggest reliability and operational efficiency. Annora Pharma's proactive engagement with regulatory bodies and its strategic market diversification further enhance its reputation as a dependable supplier in

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Annora Pharma Private Limited

How many pharmaceutical products does Annora Pharma Private Limited export from India?

Annora Pharma Private Limited exports 13 pharmaceutical products across 9 therapeutic categories. The top exports are Calcium ($10.0M), Magnesium ($8.6M), Atorvastatin ($8.4M), Famotidine ($8.1M), Mesalamine ($7.8M). Total export value is $56.8M.

What is Annora Pharma Private Limited's total pharmaceutical export value?

Annora Pharma Private Limited's total pharmaceutical export value is $56.8M, based on 2,057 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Annora Pharma Private Limited cover?

Annora Pharma Private Limited exports across 9 therapeutic categories. The largest are Gastrointestinal (38.0%, 3 products), Vitamins & Supplements (32.6%, 2 products), Cardiovascular (15.6%, 2 products).

Get Full Annora Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.